Aplastic Anemia

Ask the Pediatric Experts: Session from the Patient and Family Conference in Salt Lake City, UT 2023

Thumbnail for video Watch Now

Topic(s)

Related Bone Marrow Failure Diseases and Malignancies

Pediatric Bone Marrow Failure Diseases

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Bone Marrow Transplant

Aplastic Anemia

Myelodysplastic Syndromes (MDS)

Presenter(s)

Suneet Agarwal, MD, PhD

Michael Pulsipher, MD

Suneet Agarwal, MD, PhD, from Boston Children's Hospital answered parents' questions in this session from the Patient and Family Conference in Salt Lake City, Utah. Find the answers to your most pressing question in this recording.

Aplastic Anemia Non-Transplant Therapies - Patient and Family Conference in Salt Lake City, UT 2023

Thumbnail for video Watch Now

Topic(s)

Aplastic Anemia

Presenter(s)

Srinivas Tantravahi, MBBS, MRCP

Srinivas Tantravahi, MBBS, MRCP (UK) of Huntsman Cancer Institute explains which non-transplant therapies may be considered for treatment of aplastic anemia.

Predisposition to Inherited Bone Marrow Failure Syndromes from Patient & Family Conference UT 2023

Thumbnail for video Watch Now

Topic(s)

Pediatric Bone Marrow Failure Diseases

Aplastic Anemia

Myelodysplastic Syndromes (MDS)

Presenter(s)

Suneet Agarwal, MD, PhD

Suneet Agarwal, MD, PhD from Boston's Children's Hospital provides essential information for families about inherited bone marrow failure disorders in this session from the Patient and Family Conference in Salt Lake City, UT, 2023

Suneet Agarwal, MD, PhD

Institution

Boston Children's Hospital

Physician Status

accepting new patients

Primary Disease Area of Focus

Aplastic Anemia

Pediatric

Read more about Suneet Agarwal, MD, PhD

Conditional survival and standardized mortality ratios of patients with severe aplastic anemia surviving at least one year after hematopoietic cell transplantation or immunosuppressive therapy

Read more about Conditional survival and standardized mortality ratios of patients with severe aplastic anemia surviving at least one year after hematopoietic cell transplantation or immunosuppressive therapy

Immunosuppressive treatment (IST) and hematopoietic cell transplant (HCT) are standard therapies for severe aplastic anemia aplastic anemia: (ay-PLASS-tik uh-NEE_mee-uh) A rare

Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia

Read more about Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia

Severe aplastic anemia aplastic anemia: (ay-PLASS-tik uh-NEE_mee-uh) A rare and serious condition in which the bone marrow fails to make enough blood cells - red blood cells, w

Cyclosporine plus eltrombopag in the treatment of aplastic anemia with or without antithymocyte immunoglobulin: A multicenter real-world retrospective study

Read more about Cyclosporine plus eltrombopag in the treatment of aplastic anemia with or without antithymocyte immunoglobulin: A multicenter real-world retrospective study

Aims: To compare cyclosporine cyclosporine: Cyclosporine is used along with antithymocyte globulin (ATG), another immunosuppressant, for treating aplastic anemia and

Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study

Read more about Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study

Immune severe aplastic anemia aplastic anemia: (ay-PLASS-tik uh-NEE_mee-uh) A rare and serious condition in which the bone marrow fails to make enough blood cells - red blood c

IPSS-M in myelodysplastic neoplasms arising from aplastic anemia and paroxysmal nocturnal hemoglobinuria

Read more about IPSS-M in myelodysplastic neoplasms arising from aplastic anemia and paroxysmal nocturnal hemoglobinuria

Clonal evolution in aplastic anemia: failed tumor surveillance or maladaptive recovery?

Read more about Clonal evolution in aplastic anemia: failed tumor surveillance or maladaptive recovery?

Clonal evolution to secondary paroxysmal nocturnal hemoglobinuria paroxysmal nocturnal hemoglob

Subscribe to Aplastic Anemia

Your Gift Today Changes Lives

Aplastic Anemia

Ask the Pediatric Experts: Session from the Patient and Family Conference in Salt Lake City, UT 2023

Aplastic Anemia Non-Transplant Therapies - Patient and Family Conference in Salt Lake City, UT 2023

Predisposition to Inherited Bone Marrow Failure Syndromes from Patient & Family Conference UT 2023

Suneet Agarwal, MD, PhD

Conditional survival and standardized mortality ratios of patients with severe aplastic anemia surviving at least one year after hematopoietic cell transplantation or immunosuppressive therapy

Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia

Cyclosporine plus eltrombopag in the treatment of aplastic anemia with or without antithymocyte immunoglobulin: A multicenter real-world retrospective study

Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study

IPSS-M in myelodysplastic neoplasms arising from aplastic anemia and paroxysmal nocturnal hemoglobinuria

Clonal evolution in aplastic anemia: failed tumor surveillance or maladaptive recovery?

Website Feedback

Patient Helpline